Acute Coffee Ingestion Does Not Affect LDL Cholesterol Level

2005 ◽  
Vol 39 (7-8) ◽  
pp. 1209-1213 ◽  
Author(s):  
Rebecca J Cheung ◽  
Eric K Gupta ◽  
Matthew K Ito
Keyword(s):  
Lipid Analysis ◽  
Low Density Lipoprotein ◽  
Plasma Lipid ◽  
Coffee Consumption ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Open Label ◽  
Clinically Significant ◽  
To Receive

BACKGROUND Although patients are instructed to abstain from food before having blood drawn for lipid analysis, many still drink coffee in the morning. It is unknown whether coffee consumed prior to drawing blood samples will impact fasting serum lipids. OBJECTIVE To determine whether a single 6-oz cup of coffee with or without the addition of nondairy creamer and sugar will significantly affect fasting plasma lipid profiles. METHODS This was a prospective, open-label, randomized crossover study. At the first of 2 visits, blood was drawn to measure initial fasting lipid panels, and participants were randomized to drink 6 oz of black coffee or coffee with nondairy creamer and sugar. Within 30–60 minutes of coffee consumption, blood was drawn for follow-up lipid panels. The procedure was repeated at the second visit, except the participants were crossed over to receive the alternate coffee preparation. RESULTS Forty participants (26 men; age [mean ± SD] 45 ± 15 y) were enrolled. Total cholesterol (TC) increased from 188.2 ± 38.1 to 191.3 ± 39.9 mg/dL (p = 0.019) and high-density lipoprotein cholesterol (HDL-C) increased from 43.2 ± 12.3 to 44.8 ± 12.9 mg/dL (p < 0.001) after consumption of black coffee. Triglycerides decreased from 145.6 ± 123.7 to 136.3 ± 107.1 mg/dL (p = 0.014) after consumption of coffee with nondairy creamer and sugar. Changes in other lipid parameters, such as low-density lipoprotein cholesterol in either group, were not statistically significant. CONCLUSIONS A single cup of coffee consumed within one hour before drawing blood resulted in statistically, but not clinically, significant differences in TC and HDL-C (black coffee) and triglycerides (coffee with creamer and sugar).

Abstract P43: Frequency and Predictors of Low-Density Lipoprotein Cholesterol Control and Appropriate Response to Elevated LDL-C Levels in Patients with Cardiovascular Disease

2011 ◽  
Vol 4 (suppl_2) ◽  
Author(s):  
Salim S Virani ◽  
Lechauncy D Woodard ◽  
Supicha Sookanan ◽  
Cassie R Landrum ◽  
Tracy H Urech ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Low Density Lipoprotein ◽  
Medication Possession Ratio ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Lipid Lowering ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
To Receive

Background: Although current cholesterol performance measures define good quality as low density lipoprotein cholesterol (LDL-C) levels < 100mg/dl in cardiovascular disease (CVD) patients, they provide a snap shot at one time point and do not inform whether an appropriate action was taken to manage elevated LDL-C levels. We assessed frequency and predictors of this appropriate response (AR). Methods: We used administrative data to assess 22,902 CVD patients receiving care in a Veterans Affairs network of 7 hospitals and affiliated clinics. We determined the proportion of CVD patients at LDL-C goal <100 mg/dl, and the proportion of patients with uncontrolled LDL-C levels (>100 mg/dl) who had an AR [defined as the initiation or dosage increase of a lipid lowering medication (LLM), addition of a new LLM, receipt of maximum dosage or >1 LLM, or LDL-C reading <100 mg/dl] at 45 days follow-up. Logistic regression was performed to evaluate facility, provider and patient characteristics associated with AR. Results: LDL-C levels were at goal in 16,350 (71.4%) patients. An additional 2,110 (9.2%) had an AR at 45 days of follow-up. Controlling for clustering between facilities and patient's illness severity, history of diabetes (OR 1.18, 95% CI 1.03-1.35), hypertension (OR 1.21, 95% CI 1.02-1.44), patients showing good medication adherence (medication possession ratio > 0.8) [OR 2.29, 95% CI 1.99-2.64] were associated with AR. Older CVD patients (age >75 years) were less likely to receive AR (OR 0.60, 95% CI 0.52-0.70). Teaching vs. non-teaching facility (p=0.40), physician vs. non-physician provider (p=0.14), specialist vs. non-specialist primary care provider (p=0.12), and patient's race (p=0.12) were not predictors of AR. Conclusion: Among patients with CVD and LDL-C above guideline recommended levels, only one-third receive AR. Diabetic and hypertensive CVD patients are more likely to receive AR, whereas older Veterans with CVD receive AR less often likely reflecting providers' belief of lack of efficacy from treatment intensification in older CVD patients. Our findings are important for quality improvement and policy making initiatives as they provide more actionable information compared with isolated LDL-C goal attainment as a quality indicator.

scholarly journals Low density lipoprotein cholesterol and all-cause mortality rate: findings from a study on Japanese community-dwelling persons

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Ryuichi Kawamoto ◽  
Asuka Kikuchi ◽  
Taichi Akase ◽  
Daisuke Ninomiya ◽  
Teru Kumagi
Keyword(s):  
Low Density Lipoprotein ◽  
Critical Role ◽  
Density Lipoprotein ◽  
Community Dwelling ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Adjusted Relative Risk ◽  
Low Density Lipoprotein Cholesterol ◽  
All Cause Mortality

Abstract Background Low-density lipoprotein cholesterol (LDL-C) independently impacts aging-related health outcomes and plays a critical role in cardiovascular diseases (CVDs). However, there are limited predictive data on all-cause mortality, especially for the Japanese community population. In this study, it was examined whether LDL-C is related to survival prognosis based on 7 or 10 years of follow-up. Methods Participants included 1610 men (63 ± 14 years old) and 2074 women (65 ± 12 years old) who participated in the Nomura cohort study conducted in 2002 (first cohort) and 2014 (second cohort) and who continued throughout the follow-up periods (follow-up rates: 94.8 and 98.0%). Adjusted relative risk estimates were obtained for all-cause mortality using a basic resident register. The data were analyzed by a Cox regression with the time variable defined as the length between the age at the time of recruitment and that at the end of the study (the age of death or censoring), and risk factors including gender, age, body mass index (BMI), presence of diabetes, lipid levels, renal function, serum uric acid levels, blood pressure, and history of smoking, drinking, and CVD. Results Of the 3684 participants, 326 (8.8%) were confirmed to be deceased. Of these, 180 were men (11.2% of all men) and 146 were women (7.0% of all women). Lower LDL-C levels, gender (male), older age, BMI under 18.5 kg/m2, and the presence of diabetes were significant predictors for all-cause mortality. Compared with individuals with LDL-C levels of 144 mg/dL or higher, the multivariable-adjusted Hazard ratio (and 95% confidence interval) for all-cause mortality was 2.54 (1.58–4.07) for those with LDL-C levels below 70 mg/dL, 1.71 (1.15–2.54) for those with LDL-C levels between 70 mg/dL and 92 mg/dL, and 1.21 (0.87–1.68) for those with LDL-C levels between 93 mg/dL and 143 mg/dL. This association was particularly significant among participants who were male (P for interaction = 0.039) and had CKD (P for interaction = 0.015). Conclusions There is an inverse relationship between LDL-C levels and the risk of all-cause mortality, and this association is statistically significant.

scholarly journals Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Kausik K. Ray ◽  
Stefano Del Prato ◽  
Dirk Müller-Wieland ◽  
Bertrand Cariou ◽  
Helen M. Colhoun ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Atherosclerotic Cardiovascular Disease ◽  
Open Label ◽  
Double Blind ◽  
Mixed Dyslipidemia

Abstract Background Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and LDL particle number (LDL-PN). The presence of atherosclerotic cardiovascular disease (ASCVD) increases the risk of future cardiovascular events. We evaluated the efficacy and safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, among individuals with type 2 diabetes (T2DM), high LDL-C or non-HDL-C, and established ASCVD receiving maximally tolerated statin in ODYSSEY DM-DYSLIPIDEMIA (NCT02642159) and DM-INSULIN (NCT02585778). Methods In DM-DYSLIPIDEMIA, individuals with T2DM and mixed dyslipidemia (non-HDL-C ≥ 100 mg/dL; n = 413) were randomized to open-label alirocumab 75 mg every 2 weeks (Q2W) or usual care (UC) for 24 weeks, with UC options selected before stratified randomization. In DM-INSULIN, insulin-treated individuals with T2DM (LDL-C ≥ 70 mg/dL; n = 441) were randomized in a double-blind fashion to alirocumab 75 mg Q2W or placebo for 24 weeks. Study participants also had a glycated hemoglobin < 9% (DM-DYSLIPIDEMIA) or < 10% (DM-INSULIN). Alirocumab dose was increased to 150 mg Q2W at week 12 if week 8 LDL-C was ≥ 70 mg/dL (DM-INSULIN) or non-HDL-C was ≥ 100 mg/dL (DM-DYSLIPIDEMIA). Lipid reductions and safety were assessed in patients with ASCVD from these studies. Results This analysis included 142 DM-DYSLIPIDEMIA and 177 DM-INSULIN participants with ASCVD, including 95.1% and 86.4% with coronary heart disease, and 32.4% and 49.7% with microvascular diabetes complications, respectively. At week 24, alirocumab significantly reduced LDL-C, non-HDL-C, ApoB, and LDL-PN from baseline versus control. This translated into a greater proportion of individuals achieving non-HDL-C < 100 mg/dL (64.6% alirocumab/23.8% UC [DM-DYSLIPIDEMIA]; 65.4% alirocumab/14.9% placebo [DM-INSULIN]) and ApoB < 80 mg/dL (75.1% alirocumab/35.4% UC and 76.8% alirocumab/24.8% placebo, respectively) versus control at week 24 (all P < 0.0001). In pooling these studies, 66.4% (alirocumab) and 67.0% (control) of individuals reported treatment-emergent adverse events. The adverse event pattern was similar with alirocumab versus controls. Conclusions Among individuals with T2DM and ASCVD who had high non-HDL-C/LDL-C levels despite maximally tolerated statin, alirocumab significantly reduced atherogenic cholesterol and LDL-PN versus control. Alirocumab was generally well tolerated. Trial registration Clinicaltrials.gov. NCT02642159. Registered 30 December 2015 and Clinicaltrials.gov. NCT02585778. Registered 23 October 2015

scholarly journals Role of Vernonia Amygdalina on Plasma Lipid Profile, Liver and Kidney Enzymes in Rats with Streptozotocin-Induced Diabetes

2020 ◽  
pp. 93-102
Author(s):  
Gabriel Olukayode Ajayi ◽  
Elvis Uchechukwu Obi ◽  
Elizabeth Namesegua Elegbeleye ◽  
Precious Titilayo Obayemi ◽  
Oyindamola Mary Edamisan
Keyword(s):  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Plasma Lipid ◽  
Density Lipoprotein ◽  
Diabetic Rats ◽  
Lipoprotein Cholesterol ◽  
Vernonia Amygdalina ◽  
Liver And Kidney ◽  
Streptozotocin Induced Diabetes

Diabetes mellitus is a non-communicable disease which has been associated with liver and kidney injuries, and at the same time affects lipid profiles. The aim of this study was to investigate the role of Vernonia amygdalina (VAM) on plasma lipid profile, liver and kidney enzymes in rats with streptozotocin -induced diabetes. Twenty-five male albino wistar rats weighing between 137 and 223 g were randomly grouped into five of five rats per group as follows: control, diabetic, diabetic + metformin (MET), diabetic + VAM at 150, 300 mg/kg. Diabetes was induced by administration of 45 mg/kg body weight streptozotocin (STZ) dissolved in citrate buffer (0.01 M, pH 4.5) by single intraperitoneal injection. Three days after, when diabetes was confirmed, MET and VAM were administered daily by oral gavage for 7 days. Animals were fasted overnight after the last administration of MET and VAM, sacrificed, blood was collected and plasma prepared for lipid profile estimation. Liver and kidney were collected, weighed, homogenized and supernatants obtained for enzymes and biochemical assays. There were no significant (p>0.05) change in the weights of animal, liver and kidney, liver/rat and kidney/rat ratios, plasma cholesterol (CHOL) concentration, activities of liver and kidney aspartate aminotransferase (AST), alanine aminotransferase (ALT), liver gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), and liver and kidney total protein (TPRO) concentrations; significant (p<0.05) decrease in triglyceride (TRIG), high density lipoprotein-cholesterol (HDL), low density lipoprotein-cholesterol (LDL), very low density lipoprotein-cholesterol (VLDL); and significant (p<0.05) increase in fasting blood glucose (FBG) level, kidney GGT, LDH activities, liver and kidney creatinine (CREA) and total bilirubin (TBIL) concentrations of diabetic (STZ) rats compared with normal control. The treatment of the diabetic rats with MET and VAM significantly modulated positively these parameters compared with the diabetic rats. This study further explains the protective role played by VAM in dyslipidaemia, liver and kidney injuries resulting from diabetes.

scholarly journals PCSK9 gene participates in the development of primary dyslipidemias

2021 ◽  
Vol 24 (1) ◽  
pp. 5-14
Author(s):  
D Matías-Pérez ◽  
AD Pérez-Santiago ◽  
MA Sánchez Medina ◽  
JJ Alpuche Osorno ◽  
IA García-Montalvo
Keyword(s):  
Cardiovascular Disease ◽  
Low Density Lipoprotein ◽  
Plasma Lipid ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Atheromatous Plaque ◽  
Statin Intolerance ◽  
Blood Concentrations ◽  
Pcsk9 Gene ◽  
Atherosclerotic Plaque Formation

Abstract Dyslipidemias are a group of diseases, which are characterized by abnormal blood concentrations of cholesterol, triglycerides and/or low-density lipoprotein-cholesterol (LDL-c). Dyslipidemia is a determinant condition for the progress of an atherosclerotic plaque formation. The resulting atherogenicity is due to at least two mechanisms: first, to the accumulation in the plasma of lipid particles that have the capacity to alter the function of the endothelium and deposit at the atheromatous plaque, and second, at an insufficient concentration of multifactorial type of high density lipoprotein-cholesterol (HDL-c), whose function is to protect against the development of atherosclerosis. Its highest prevalence is encountered among individuals with diabetes, hypertension or overweight. Hyperlipidemia is one of the main predisposing factors for the development of cardiovascular disease. Hyperlipidemia can be the result of a genetic condition, the secondary expression of a primary process or the consequence of exogenous factors (food, cultural, socio-economic, etc.), all of which lead to the elevation of plasma lipid levels. The objective of this study was to carry out an analysis of the genes involved in the development of dyslipidemias that lead to cardiovascular disease with special emphasis on the proprotein convertase subtilin/kexin type 9 (PCSK9) gene. The PCSK9 gene participates in the development of primary dyslipidemias, mainly familial hypercholesterolemia, currently the pharmacological treatment of choice to reduce LDL-c are statins, however, it has been observed that these have been insufficient to eliminate cardiovascular risk, especially in subjects with primary forms of hypercholesterolemia related to genetic mutations, or statin intolerance.

scholarly journals Relationship between Plasma Lipidomics and Carotid Atherosclerotic Plaque

2020 ◽  
Author(s):  
Gaoqiang Xie ◽  
Phyo Kyaw Myint ◽  
Zhongze Fang ◽  
Ying Yang ◽  
Wenyao Ma ◽  
...  
Keyword(s):  
Vegetable Intake ◽  
Wide Spectrum ◽  
Low Density Lipoprotein ◽  
Plasma Lipid ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Lipid Species ◽  
Lipid Components

Abstract Background: The rapidly growing discipline of lipidomics allows the study of a wide spectrum of lipid species in human plasma and provides new insights into the pathogenesis of atherosclerosis. Objective: To explore the roles of plasma lipid components in relation to atherosclerotic plaques.Methods: Ten non-symptomatic persons (age 62.42±3.45) with 2 or more carotid plaques (soft or mixed) and ten apparently healthy controls without any carotid plaque (age 62.82±4.38), were randomly selected as cases and controls from a community-based sample of 1312 persons. Ultra-performance liquid chromatography coupled with electrospray ionization quadrupole mass spectrometry (UPLC-ESI-QTOF MS)-based lipidomics was used to measure lipid components. The difference of lipid species between cases and controls was analyzed by t-test and general linear regression. Results: Among 53 lipid components, significantly elevated plasma levels of one novel individual ceramide species (ceramide 22: 0) were observed in cases compared to the controls (0.59±0.18 versus 0.41±0.10μg/mL, p values<0.05). After adjusting for confounding factors, such as total cholesterol and low-density lipoprotein cholesterol, the results remained significant (p<0.05). 22:0 ceramide was significantly negatively correlated with vegetable intake (r=-0.74, p=0.014).Conclusion: High level of plasma ceramide 22:0 may be a novel risk factor for carotid atherosclerosis in human which independent of cholesterol and low-density lipoprotein cholesterol, it deserves future studies with larger sample size to confirm.

Sign in / Sign up

Export Citation Format

Share Document